雄激素剥夺治疗与合并症变化:GnRH激动剂与抗雄激素单药治疗高危前列腺癌的比较
这项基于瑞典前列腺癌数据库3.0的人群登记研究,比较了晚期非转移性前列腺癌患者接受GnRH激动剂(n=4878)或抗雄激素单药(n=2078)治疗后合并症的变化。结果显示,GnRH激动剂组在开始ADT后CCI超额变化率高于抗雄激素单药组(每年5.6%,p<0.001),且任何新增CCI变化的风险更高(HR 1.32,95%CI 1.20-1.44)。结论认为抗雄激素单药对合并症的影响低于GnRH激动剂。
要点
- GnRH激动剂组CCI超额变化率比抗雄激素单药组高每年5.6%(p<0.001)。
- GnRH激动剂组任何新增CCI变化的风险是抗雄激素单药组的1.32倍(95%CI 1.20-1.44)。
- 抗雄激素单药治疗对合并症的影响低于GnRH激动剂。
核心结论
- 对于晚期非转移性前列腺癌患者,抗雄激素单药治疗对合并症的影响低于GnRH激动剂。
研究设计与样本
- 基于瑞典前列腺癌数据库3.0的人群登记研究,纳入接受原发性抗雄激素单药治疗(n=2078)或GnRH激动剂治疗(n=4878)的晚期非转移性前列腺癌男性,并选取年龄和地区匹配的无前列腺癌男性作为对照。
- 使用Charlson合并症指数(CCI)测量从开始ADT前5年至后5年的合并症增加情况。
- 采用多变量线性回归分析ADT开始前后CCI变化超额率的差异,采用多变量Cox回归分析ADT后任何CCI增量变化的风险。
主要发现
- GnRH激动剂组开始ADT后CCI变化超额率与抗雄激素单药组相比差异为每年5.6%(p<0.001)。
- GnRH激动剂组ADT后任何新增CCI变化的风险高于抗雄激素单药组(HR 1.32,95%CI 1.20-1.44)。
临床怎么用
- 在晚期非转移性前列腺癌且不适合根治性治疗的患者中,选择雄激素剥夺治疗方案时可考虑抗雄激素单药治疗以降低合并症风险。
- 研究结果需通过比较抗雄激素单药与GnRH激动剂的有效性和不良反应的随机试验进一步确认。
局限性
- 研究结果为观察性登记研究,需随机试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some studies suggest that gonadotropin-releasing hormone (GnRH) agonists are associated with higher risk of adverse events than antiandrogens (AAs) monotherapy. However, it has been unclear whether this is due to indication bias. OBJECTIVE: To investigate rates of change in comorbidity for men on GnRH agonists versus AA monotherapy in a population-based register study. DESIGN, SETTING, AND PARTICIPANTS: Men with advanced nonmetastatic prostate cancer (PCa) who received primary AA (n=2078) or GnRH agonists (n=4878) and age- and area-matched PCa-free men were selected from Prostate Cancer Database Sweden 3.0. Increases in comorbidity were measured using the Charlson Comorbidity Index (CCI), from 5yr before through to 5yr after starting androgen deprivation therapy (ADT). OUTCOME MEASURES AND STATISTICAL METHODS: Multivariable linear regression was used to determine differences in excess rate of CCI change before and after ADT initiation. Risk of any incremental change in CCI following ADT was assessed using multivariable Cox regression analyses. RESULTS AND LIMITATIONS: Men on GnRH agonists experienced a greater difference in excess rate of CCI change after starting ADT than men on AA monotherapy (5.6% per yr, p<0.001). Risk of any new CCI change after ADT was greater for GnRH agonists than for AA (hazard ratio, 1.32; 95% confidence interval, 1.20-1.44). CONCLUSIONS: Impact on comorbidity was lower for men on AA monotherapy than for men on GnRH agonists. Our results should be confirmed through randomised trials of effectiveness and adverse effects, comparing AA monotherapy and GnRH agonists in men with advanced nonmetastatic PCa who are unsuitable for curative treatment. PATIENT SUMMARY: Hormone therapies for advanced prostate cancer can increase the risk of other diseases (eg, heart disease, diabetes). This study compared two common forms of hormone therapy and found that the risk of another serious disease was higher for those on gonadotropin-releasing hormone agonists than for those on antiandrogen monotherapy.
引用
- Beckmann K, Garmo H, Adolfsson J, et al. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. Eur Urol. 2018. PMID: 30497883. doi:10.1016/j.eururo.2018.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。